Recent News Releases

VIFOR PHARMA ANNOUNCED TODAY THAT VIT-2763, THE FIRST-EVER ORAL FERROPORTIN INHIBITOR FOR PREVENTING IRON OVERLOAD WILL ENTER CLINICAL DEVELOPMENT WITH A PHASE-I STUDY AT THE BEGINNING OF MARCH...

Conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA Significant milestone further strengthens Kidney...

Klicken Sie hier für Deutsch Veuillez cliquer ici pour français SWISSMEDIC HAS APPROVED PATIROMER TO BE MARKETED IN SWITZERLAND AS VELTASSA® FOR THE TREATMENT OF HYPERKALAEMIA (ELEVATED SERUM...

Dr Brian McNamee AO and Mr Abbas Hussain have been appointed as independent Non-Executive Directors, effective 14 February 2018. CSL (ASX:CSL; USOTC:CSLLY) today announced that Dr Brian McNamee AO...

CSL Behring today announced that it has signed an agreement with the National Blood Authority, representing all Australian governments, to continue to provide the community with a world-class and...

CSL today officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows with the assistance of Victorian Minister for Industry and Employment, Ben...

05 Dec 2017 Melbourne, Australia and Vancouver, Canada: CSL Limited (ASX:CSL; USOTC:CSLLY) and Vitaeris Inc. (Vitaeris) today announced that they have entered into a strategic collaboration and...

The study will be the largest ever undertaken by CSL, and will enroll more than 17,000 patients from approximately 1,000 sites around the world. Jemimah Pentland 05 Dec 2017 Global biotherapeutics...

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases

This decision comes after Public Health England declared that conventional non-adjuvanted influenza vaccines provided little or no protection for adults aged 65 years and over in the 2016-17 flu...